

Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/gpss20

Synthesis of Some Bicyclic Thiazolopyrimidine Derivatives

A. Mobinikhaledi^a, N. Forughifar^a & F. Goodarzi^a ^a University of Arak, Arak, Iran

Published online: 18 Jun 2010.

To cite this article: A. Mobinikhaledi , N. Forughifar & F. Goodarzi (2003): Synthesis of Some Bicyclic Thiazolopyrimidine Derivatives, Phosphorus, Sulfur, and Silicon and the Related Elements, 178:12, 2539-2543

To link to this article: <u>http://dx.doi.org/10.1080/714040967</u>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <u>http://www.tandfonline.com/page/terms-and-conditions</u>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.



SYNTHESIS OF SOME BICYCLIC THIAZOLOPYRIMIDINE DERIVATIVES

A. Mobinikhaledi, N. Forughifar, and F. Goodarzi University of Arak, Arak, Iran

(Received April 23, 2003; accepted June 26, 2003)

Thiazolopyrimidine compounds 3(a-d) were synthesized by a simple one-pot condensation reaction of starting pyrimidine derivative 1 and 1,2-dibromoethane 2 in dimethylformamide. In a similar way thiazolopyrimidine compounds 5(a-e) were synthesized by reaction of 1 and 2-bromopropionic acid 4 in dioxane under reflux condition. The yields of products following recrystallization from ethanol were of the order of 70–80%.

Keywords: 1,2-Dibromoethane; 2-bromopropionic acid; carboxylate; pyrimidine; thiazolo

Pyrimidine derivatives are known as important heterocyclic compounds for their considerable antibacterial and antifungal activities. Some pyrimidines possess remarkable pharmacological efficiency.^{1–16} As a result pyrimidine has been subjected to a large variety of structural modifications in order to synthesize derivatives with different biological effects. Various synthetic approaches for the synthesis of pyrimidine derivatives have been reported in the literature.^{1,17–20} Most of them are based on the simple Biginelli cyclocondensation reaction of β -ketoester, aryl aldehyde, and thio (urea) derivatives,^{1,17,18} and in some case they are based on multi-step processes.¹⁹

Here, due to versatile biological properties of pyrimidine derivatives, we have extended the general method of Kappe¹⁸ in order to synthesize some novel bicyclic pyrimidine derivatives in high yield.

Address correspondence to A. Mobinikhaledi, Chemistry Department, University of Arak, Dr. Beheshti Ave, Arak, Iran. E-mail: akbar_mobini@yahoo.com

RESULTS AND DISCUSSION

Compounds $3(\mathbf{a}-\mathbf{d})$ and $5(\mathbf{a}-\mathbf{b})$ were synthesized according to procedures A and B respectively.¹⁸ Reaction of the starting pyrimidine derivative 1 and 1,2-dibromoethane 2 in dimethylformamide under reflux afforded $3(\mathbf{a}-\mathbf{d})$ as HBr salts (Scheme 1). Also reaction of 1 and 2bromopropionic acid 3 as an cyclocondensation reagent in dioxane under reflux gave compounds $5(\mathbf{a}-\mathbf{e})$. These methods are very easy and can be used to prepare various substituted thiazolopyrimidine compounds (Scheme 1).

Reactions were usually carried out for 2 to 4 h. Yields of these onepot protocol reactions following recrystallization from ethanol were of



the order of 70–80%. In the IR spectra of compounds 3(a-d) and 5(a-e) absence of the absorption at 3200–3400 cm⁻¹, the characteristic absorption of NH group of starting material, is a good evidence of the expected reactions.

EXPERIMENTAL

Pyrimidine thiazole derivatives were prepared using the method of Kappe et al.¹⁸ Melting points were determined with an electrothermal digital melting point apparatus. IR spectra were recorded on a Galaxy series FT-IR 5000 spectrophotometer by using KBr pellets. ¹HNMR spectra were recorded on Bruker 400 and 500 MHz spectrometers with using Me₄Si (TMS) as an internal standard. mass spectra were measured with an EI (70 eV)+Q1MSLMR up LP spectrometer. Reaction courses and product mixtures were monitored by thin layer chromatography.

Procedure A

Compound **3** was prepared as a HBr salt. 1,2-Dibromoethane (0.001 mmol) was added to a boiling solution of appropriate pyrimidine thiazole derivatives (0.001 mmol) in dimethylformamide (2 ml) and then refluxed for 2 to 4 h. The reaction mixture was cooled and the precipitate filtered off and washed with ethanol. The crude product was recrystallized from ethanol. This procedure was used for synthesis of compounds $3(\mathbf{a-d})$.

Ethyl-5-(4-methylphenyl)-2,3-dihydro-7-methyl-5H-thiazolo [3,2-a]pyrimidine-6-carboxylate (3a) . Yield % 75, m.p. 202–204°C. IR (KBr): v = 3100, 2985, 1693, 1535, 1300, 1110 cm⁻¹. ¹HNMR (DMSO-d₆): $\delta = 1.05$ (t, 3H, -CH₃), 2.3 (s, 3H, -CH₃), 2.6 (m, 4H, -CH₂-CH₂), 3.69 (q, 2H, -CH₂), 5.71 (s, 1H, H-5), 7.3 (m, 4H, H-arom). Ms: m/z (%) = 315 (M⁺, 24), 287 (43), 224 (100), 196.5 (45).

Ethyl-5-(2-nitrophenyl)-7-methyl-5H-thiazolo pyrimidine-6carboxylate (3b). Yield % 70, m.p. 233–234°C. IR (KBr): v = 3067, 2964, 1692, 1532, 1324, 1264 cm⁻¹. ¹HNMR (DMSO-d₆): $\delta = 1.0$ (t, 3H, –CH₃), 2.3 (s, 3H, –CH₃), 2.5 (m, 4H, –CH₂–CH₂), 3.6 (q, 2H, –CH₂), 6.1 (s, 1H, H-5), 7.6 (m, 4H, H-arom). Ms: m/z (%) = 347 (M⁺, 20), 330 (75), 298 (100), 224 (60), 196 (65).

Ethyl-5-(3-chlorophenyl)-2,3-dihydro-7-methyl-5H-thiazolo [**3,2-a]pyrimidine-6-carboxylate (3c)**. Yield % 73, m.p. 204–206°C. IR (KBr): $v = 3050, 2950, 1676, 1197, 1117 \text{ cm}^{-1}$. ¹HNMR (DMSO-d₆): $\delta = 1.0$ (t, 3H, -CH₃), 2.5 (s, 3H, -CH₃), 2.6 (m, 4H, -CH₂-CH₂), 3.7 $(q, 2H, -CH_2), 6.3 (s, 1H, H-5), 7.2 (m, 4H, H-arom).$ Ms: m/z (%) = 336 (M⁺, 48), 307 (85), 224 (90), 195.5 (100), 150 (30).

Ethyl-5-(2,5-dimethoxyphenyl)-2,3-dihydro-7-methyl-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate (3d). Yield % 80, m.p. 211– 212°C. IR (KBr): v = 3060, 2960, 1670, 1530, 1312 cm⁻¹. ¹HNMR (DMSO-d₆): $\delta = 1.07$ (t, 3H, -CH₃), 2.34 (s, 3H, -CH₃), 2.90 (m, 4H, -CH₂-CH₂), 3.96 (q, 2H, -CH₂), 3.72 (s, 6H, -OCH₃), 5.86 (s, 1H, H-5), 6.91 (m, 3H, H-arom). Ms: m/z (%) = 362 (M⁺, 48), 333 (80), 289.2 (35), 224.7 (100), 196 (100), 152.90 (40), 150 (25).

Procedure B

A mixture of appropriate pyrimidine thiazole derivatives, (0.001 mmol) and 2-bromo propionic acid (0.001 mmol) in dioxane (3 ml) were refluxed for 1 to 2 h. The reaction mixture was cooled and the precipitate filtered off and then washed with ethanol. The crude product was recrystallized from ethanol. This procedure was used for synthesis of compounds $5(\mathbf{a-e})$.

Ethyl-2,7-dimethyl-3-oxo-5-phenyl-2,3-dihydro-5H-thiazolo [**3,2,a**]**pyrimidine-6-carboxylate** (**5a**). Yield % 80, m.p. 216°C. IR (KBr): $\nu = 3090$, 1760, 1717, 1657, 1359 cm⁻¹. ¹HNMR (CDCl₃): $\delta = 1.17$ (t, 3H, CH₃), 2.29 (d, 3H, -CH₃), 2.40 (s, 3H, CH₃), 4.03 (q, 2H, -CH₂), 4.73 (q, 1H, CH), 6.63 (s, 1H, H-5), 7.15 (m, 5H, H-arom). Ms: m/z (%) = 330 (M⁺, 70), 302 (25), 285 (22), 273 (30), 253 (90), 225 (90), 197 (30), 67 (40).

Ethyl-2,7-dimethyl-3-oxo-5-(4-methylphenyl)-2,3-dihydro-5Hthiazolo[3,2,a]pyrimidine-6-carboxylate (5b). Yield % 73, m.p. 198°C. IR (KBr): $\upsilon = 3075$, 1757, 1685, 1595, 1283 cm⁻¹. ¹HNMR(CDCl₃): $\delta = 1.07$ (t, 3H, CH₃), 1.45 (d, 3H, CH₃), 2.51 (s, 3H, -CH₃), 4.03 (q, 2H, -CH₂), 4.68 (q, 1H, CH), 5.88 (s, 1H, H-5), 7.1 (m, 4H, Harom). Ms: m/z (%) = 344 (M⁺, 60), 316 (25), 287 (20), 271 (60), 253 (90), 225 (90), 197 (25), 169 (20), 80 (80).

Ethyl-2,7-dimethyl-3-oxo-5-(3-chorophenyl)-2,3-dihydro-5Hthiazolo[3,2,a]pyrimidine-6-carboxylate (5c). Yield % 75, m.p. 218–219°C. IR (KBr): v = 2997, 1769, 1692, 1552, 1321, 1169, 1102 cm⁻¹. ¹HNMR (CDCl₃): $\delta = 1.03$ (t, 3H, -CH₃), 1.46 (d, 3H, CH₃), 2.53 (s, 3H, -CH₃), 4.01 (q, 2H, -CH₂), 4.09 (q, 1H, CH), 5.95 (s, 1H, H-5), 7.13 (m, 4H, H-arom). Ms: m/z (%) = 364 (M⁺, 30), 336 (20), 307 (15), 253 (90), 225 (90), 197 (30), 80 (60).

Ethyl-2,7-dimethyl-3-oxo-5-(2,5-dimethoxyphenyl)-2,3-dihydro-5H-thiazolo[3,2,a]pyrimidine-6-carboxylate (5d). Yield % 80, m.p. 198–200°C. IR (KBr): v = 2953, 2731, 1763, 1712, 1662, 1278 cm⁻¹. ¹HNMR (CDCl₃): $\delta = 1.07$ (t, 3H, -CH₃), 1.51 (d, 3H, CH₃), 2.34 (s, 3H, $-CH_3$), 3.70 (s, 6H, 2-OMe), 4.03 (q, 2H, $-CH_2$), 4.70 (q, 1H, CH), 6.04 (s, 1H, H-5), 6.90 (m, 3H, H-arom). Ms: m/z (%) = 390 (M⁺, 75), 359 (50), 334 (25), 253 (90), 225 (90), 197 (25), 181 (35), 153 (20), 80 (45).

Ethyl-2,7-dimethyl-3-oxo-5-[4-(N,N-dimethylamino)phenyl]-2,3-dihydro-5H-thiazolo[3,2,a]pyrimidine-6-carboxylate (5e). Yield % 80, m.p. 213–215°C. IR (KBr): v = 2970, 1762, 1683, 1558, 1278, 1175 cm⁻¹. ¹HNMR (CDCl₃): $\delta = 1.04$ (t, 3H, –CH₃), 1.46 (d, 3H, CH₃), 2.70 (s, 3H, –CH₃), 3.51 (s, 6H, –N(CH₃)₂), 4.02 (q, 2H, –CH₂), 4.07 (q, 1H, CH), 6.40 (s, 1H, H-5), 7.80 (m, 4H, H-arom). Ms: m/z (%) = 373 (M⁺, 90), 317 (25), 300 (20), 272 (70), 253 (90), 225 (90), 80 (80).

REFERENCES

- [1] C. O. Kappe, Tetrahedron, 49, 6937 (1993).
- [2] R. S. Varma, Green. Chem., 43 (1999).
- [3] K. S. Atwal, B. N. Swanson, S. E. Unger, et al., J. Med. Chem., 34, 806 (1991).
- [4] C. G. Rovnyak, K. S. Atwal, A. Hedberg, et al., J. Med. Chem., 35, 3254 (1992).
- [5] E. L. Khania, G. O. Sillinietse, Ya. Ya. Ozel, G. Dabur, and A. A. Yakimenis, *Khim. Pharm. Zh.*, **78**, 1321 (1998).
- [6] H. Cho, M. Ueda, K. Shima, et al., J. Med. Chem., 32, 2399 (1989).
- [7] G. C. Rovnyak, S. D. Kimball, B. Bever, et al., J. Med. Chem., 38, 119 (1995).
- [8] A. Loupy, A. Petit, J. Hamelin, F. Texier-Boullet, P. Jacquault, and D. Math, Synthesis, 1213 (1998).
- [9] R. A. Abramovich, Org. Proceed Int., 23, 683 (1991).
- [10] G. C. Rovnyak, K. S. Atwal, A. Hedberg, et al., J. Med. Chem., 35, 3254 (1992).
- [11] G. J. Grover, S. Dzwonczyk, D. M. McMullen, et al., *Cardiovasc. Pharmacol.*, 26, 289 (1995).
- [12] C. O. Kappe and F. S. Falsone, Synlett, 718 (1998).
- [13] N. Foroughifar, A. Mobinikhaledi, S. M. Shariatzadeh, and M. Masoudnia, Asian Journal of Chemistry, 14, 782 (2002).
- [14] M. A. Bruce, G. S. Pointdexter, and G. Johnson, PCT Int. Apll. WO 98 33, 791.
- [15] A. K. Bose, B. K. Banik, N. Lavlinskaia, M. Jayaraman, and M. S. Manhas, *Chemtech.*, 27, 18 (1997).
- [16] M. M. Ghorba, Y. A. Mohamed, S. A. Mohamed, and Y. A. Ammar. *Phosphorus*, Sulfur, and Silicon, 108, 249 (1996).
- [17] P. Biginelli, Gazz Chim, Ital., 23, 360 (1893).
- [18] C. O. Kappe and P. Rochger, J. Heterocyclic Chem., 26, 55 (1989).
- [19] A. D. Shutalev, E. A. Kishko, N. Sivova, and A. Y. Kuznetsov, *Molecules*, 3, 100 (1989).
- [20] N. Foroughifar, A. Mobinikhaledi, and H. Fathinejad Jirandehi. *Phosphorus, Sulfur, and Silicon*, **178**, 495 (2003).